Health Care [ 7/12 ] | Biotechnology [ 56/74 ]
NASDAQ | Common Stock
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan.
The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.
It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases.
The company was founded in 1993 and is headquartered in Edmonton, Canada.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 30, 26 | 0.25 Increased by +56.25% | 0.16 Increased by +56.25% |
| Feb 26, 26 | 1.53 Increased by +15.20 K% | 0.22 Increased by +595.45% |
| Nov 4, 25 | 0.23 Increased by +130.00% | 0.16 Increased by +43.75% |
| Jul 31, 25 | 0.16 Increased by +1.50 K% | 0.15 Increased by +6.67% |
| May 12, 25 | 0.16 Increased by +328.57% | 0.10 Increased by +60.00% |
| Feb 13, 25 | 0.01 Increased by +105.26% | -0.02 Increased by +162.50% |
| Nov 7, 24 | 0.10 Increased by +211.11% | 0.02 Increased by +400.00% |
| Aug 1, 24 | 0.01 Increased by +112.50% | 0.01 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 77.70 M Increased by +24.40% | 34.35 M Increased by +47.17% | Increased by +44.21% Increased by +18.30% |
| Dec 31, 25 | 77.11 M Increased by +28.81% | 210.79 M Increased by +14.65 K% | Increased by +273.35% Increased by +11.35 K% |
| Sep 30, 25 | 73.47 M Increased by +8.41% | 31.55 M Increased by +119.87% | Increased by +42.95% Increased by +102.82% |
| Jun 30, 25 | 70.01 M Increased by +22.41% | 21.51 M Increased by +2.88 K% | Increased by +30.73% Increased by +2.33 K% |
| Mar 31, 25 | 62.47 M Increased by +24.18% | 23.34 M Increased by +317.17% | Increased by +37.37% Increased by +274.89% |
| Dec 31, 24 | 59.87 M Increased by +32.76% | 1.43 M Increased by +105.32% | Increased by +2.39% Increased by +104.01% |
| Sep 30, 24 | 67.77 M Increased by +24.32% | 14.35 M Increased by +206.72% | Increased by +21.17% Increased by +185.84% |
| Jun 30, 24 | 57.19 M Increased by +37.83% | 722.00 K Increased by +106.28% | Increased by +1.26% Increased by +104.56% |